Impact of Repeated Variant Exposures on Cellular and Humoral Immunogenicity Induced by SARS-CoV-2 Vaccines DOI Creative Commons
Leire Fernández-Ciriza, José Luís del Pozo,

Nazaret Betanzos

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(12), P. 1408 - 1408

Published: Dec. 13, 2024

Background/Objectives: The emergence of the Omicron variant has complicated COVID-19 control and prompted vaccine updates. Recent studies have shown that a fourth dose significantly protects against infection severe disease, though long-term immunity data remain limited. This study aimed to assess Anti-S-RBD antibodies interferon-γ levels in healthcare workers 12 months after receiving bivalent Original/Omicron BA.4-5 SARS-CoV-2 vaccine. Methods: In this prospective cohort study, 549 were categorized by initial vaccination schedule, with 229 individuals having received dose. Blood samples collected from all participants post-vaccination. Results: Significant differences antibody observed between those who did not, while no seen levels. After months, there significant humoral cellular response volunteers primoinfected or reinfected across different periods variant. A multivariable analysis revealed an association high (>6000 U/mL) (OR: 3.13; 95% CI: 1.3–7.7; p < 0.05). Regarding primary schedules, vaccinated ChAdOx1 (a single double dose) had notably lower compared mRNA-based vaccines. Additionally, shows higher frequency multiple infections among single-dose schedule 6.24; 1.25–31.15; 0.01). Conclusions: Overall, vaccines exhibited stronger immunogenicity. Repeated exposure seems mitigate immune imprinting wild-type SARS-CoV-2. An was strong response, although correlation not linear.

Language: Английский

Determination of T cell response against XBB variants in adults who received either monovalent wild type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster DOI Creative Commons

Yun Sang Tang,

Chee Wah Tan, Ka Chun Chong

et al.

International Journal of Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown, P. 107271 - 107271

Published: Oct. 1, 2024

Language: Английский

Citations

0
Clinical characteristics and antibody response to Omicron variants among solid carcinoma patients in China on the 2022.12–2023.4 wave of the COVID-19 pandemic DOI Creative Commons

Rongrong Dai,

Weiyu Peng,

Nani Xu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 6, 2024

Background China experienced a surge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants after adjusting its zero-coronavirus disease 2019 (COVID-19) policy. Although infections with are generally less than previous SARS-CoV-2 variants, the clinical characteristics, persistent symptoms, and antibody responses in solid carcinoma patients (SCPs) COVID-19 during wave unclear. Methods We conducted cross-sectional study April 2023, recruiting healthy controls (HCs) from community SCPs Zhejiang Provincial People’s Hospital. Serum samples were collected, questionnaire was used to assess infection status, including demographic manifestations, “long COVID” symptoms. Humoral immune analyzed by enzyme-linked immunosorbent assays (ELISAs) targeting immunoglobulin G (IgG) antibodies against receptor-binding domain (RBD; BA.4/5) protein cell culture-based neutralization (BA.4/5, BF.7, XBB.1.5, EG.5). Results In total, 298 258 HCs enrolled. Self-reported case rates significantly lower (78.5% vs. 93.8%, P&lt;0.001). Common symptoms similar between two groups, primarily comprising general (92.6% 84.9%) (51.9% 48.2%) infection. There no significant difference at 1–3 months post-infection (P=0.353); fatigue most common symptom (45.0% 44.8%). exhibited anti-RBD-IgG titers compared (1.061 1.978, P=0.001). The 50% pseudovirus titer (pVNT 50 ) values for prevalent strains (BA.4/5 BF.7) (621.0 [288.8, 1333.0] 894.1 [458.5, 1637.0] 529.6 [215.3, 1264.5] 463.1 [185.2, 914.0], respectively). Levels subsequent (XBB.1.5 EG.5) also reduced. differences among types levels variants. However, who received vaccine or had displayed higher levels. Conclusions This elucidated immunological characteristics shift away zero-COVID-19 Our findings provide insights regarding factors that influence this population.

Language: Английский

Citations

0
Long-term COVID-19 vaccine- and Omicron infection-induced humoral and cell-mediated immunity DOI Creative Commons
Milja Belik, Arttu Reinholm, Pekka Kolehmainen

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 21, 2024

Mutations occurring in the spike (S) protein of SARS-CoV-2 enables virus to evade COVID-19 vaccine- and infection-induced immunity.

Language: Английский

Citations

0
Impact of Repeated Variant Exposures on Cellular and Humoral Immunogenicity Induced by SARS-CoV-2 Vaccines DOI Creative Commons
Leire Fernández-Ciriza, José Luís del Pozo,

Nazaret Betanzos

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(12), P. 1408 - 1408

Published: Dec. 13, 2024

Background/Objectives: The emergence of the Omicron variant has complicated COVID-19 control and prompted vaccine updates. Recent studies have shown that a fourth dose significantly protects against infection severe disease, though long-term immunity data remain limited. This study aimed to assess Anti-S-RBD antibodies interferon-γ levels in healthcare workers 12 months after receiving bivalent Original/Omicron BA.4-5 SARS-CoV-2 vaccine. Methods: In this prospective cohort study, 549 were categorized by initial vaccination schedule, with 229 individuals having received dose. Blood samples collected from all participants post-vaccination. Results: Significant differences antibody observed between those who did not, while no seen levels. After months, there significant humoral cellular response volunteers primoinfected or reinfected across different periods variant. A multivariable analysis revealed an association high (>6000 U/mL) (OR: 3.13; 95% CI: 1.3–7.7; p < 0.05). Regarding primary schedules, vaccinated ChAdOx1 (a single double dose) had notably lower compared mRNA-based vaccines. Additionally, shows higher frequency multiple infections among single-dose schedule 6.24; 1.25–31.15; 0.01). Conclusions: Overall, vaccines exhibited stronger immunogenicity. Repeated exposure seems mitigate immune imprinting wild-type SARS-CoV-2. An was strong response, although correlation not linear.

Language: Английский

Citations

0